Evaluation of drug efficacy in a guinea PIG model of neonatal opioid withdrawal syndrome
Ended Awarded Last action
- Contract number
- 75N95019F00089
- Awardee
-
Lovelace Biomedical Research Institute UEI MBT9RXJJ7428
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $179,684
Award facts
- Opportunity
-
- CRO Support for NCATS Animal Model Development and In Vivo Pharmacology Studies and Related Services Pre-Solicitation · N01TR192005 · Posted Mar 13, 2018
- Contract value 100% obligated
- $179,684.31 Current and potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Albuquerque, NM 87108, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$150,986 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $76,031 | |
| Other Administrative Action | $0 | |
| Change Order | $15,987 | |
| Original award | $238,652 |
About this award
This contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences to Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization. The $179,684.31 contract is for the evaluation of drug efficacy in a guinea pig model of neonatal opioid withdrawal syndrome. This work does not have a set-aside designation. Lovelace Biomedical Research Institute has served as a prime contractor for various federal agencies, including the NIH, Department of Defense, and HHS, conducting nonclinical animal studies and preclinical research across areas like infectious diseases, drug discovery, and medical countermeasures. The organization holds multiple federal contract Indefinite Delivery Vehicles (IDVs) to provide animal modeling and preclinical product development support to agencies such as the National Institute of Allergy and Infectious Diseases, the National Center for Advancing Translational Sciences, and the Biomedical Advanced Research and Development Authority.
Quick answers
Who was awarded contract 75N95019F00089?
75N95019F00089 was awarded to Lovelace Biomedical Research Institute by National Institute on Drug Abuse (National Institutes of Health) on September 24, 2019.
How much is contract 75N95019F00089 worth?
The government has obligated $179,684 on 75N95019F00089.
Which agency awarded contract 75N95019F00089?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95019F00089, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Is contract 75N95019F00089 an order under another contract?
Yes. 75N95019F00089 is a delivery order under 75N95019D00012, an indefinite delivery contract.
Was contract 75N95019F00089 competed?
The extent of competition for 75N95019F00089 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award